Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a Hapten-modified autologous tumor vaccine

Journal of Clinical Investigation

Volumn 99, Issue 4, 1997, Pages 710-717

  Sensi, Marialuisa ^a   Farina, Cinthia ^a   Maccalli, Cristina ^a   Lupetti, Raffaella ^a   Nicolini, Gabriella ^a   Anichini, Andrea ^a   Parmiani, Giorgio ^a   Berd, David ^b,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

cytotoxic T cells; melanoma; T cell receptor; tumor infiltrating lymphocytes; vaccine

Indexed keywords

CANCER VACCINE; T LYMPHOCYTE RECEPTOR;

ARTICLE; CANCER IMMUNOLOGY; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN TISSUE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0031036659     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119215     Document Type: Article

References (37)

1. Berd, D., G. Murphy, H.C. Maguire, Jr., and M.J. Mastrangelo. 1991. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 51:2731-2734.
2. Berd, D., H.C. Maguire, Jr., M.J. Mastrangelo, and G.F. Murphy. 1994. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol. Immunother. 39:141-147.
3. Berd, D., and G. Parmiani. 1995. Human tumor vaccines go molecular. Cancer Immunol. Immunother. 41:199-200.
4. Boon, T., and P. Van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725-730.
5. Sensi, M., and G. Parmiani. 1995. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol. Today. 16:588-595.
6. Farace, F., E. Angevin, B. Escudier, A. Caignard, P.Y. Dietrich, C. Genevee, T. Hercend, and F. Triebel. 1993. Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma. Int. J. Cancer. 54:741-747.
7. Puisieux, I., J. Even, C. Pannetier, F. Jotereau, M. Favrot, and P. Kourilsky. 1994. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J. Immunol. 153:2807-2818.
8. Willhauck, M., T. Mohler, C. Scheibenbogen, M. Pawlita, P. Brossart, J.W. Schmier, and U. Keilholz. 1996. T-cell receptor B variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin. Cancer Res. 2:767-772.
9. Kumar, A., F. Farace, C. Gaudin, and F. Triebel. 1996. Clonal T cell expansion induced by interleukin 2 therapy in blood and tumors. J. Clin. Invest. 97:1219-1226.
10. Weidmann, E., T.F. Logan, S. Yasumura, J.M. Kirkwood, M. Trucco, and T.L. Whiteside. 1993. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 53:4745-4749.
11. Salvi, S., F. Segalla, S. Rao, F. Arienti, M. Sartori, G. Bratina, E. Caronni, A. Anichini, C. Clemente, G. Parmiani, and M. Sensi. 1995. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res. 55:3374-3379.
12. Genevee, C., A. Diu, J. Nierat, A. Caignard, P.Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22:1261-1269.
13. Gorski, J., M. Yassai, X. Zhu, B. Kissela, C. Keever, and N. Flomenberg. 1994. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J. Immunol. 152:5109-5119.
14. Orita, M., H. Iwahana, H. Kanazawa, K. Hayashi, and T. Sehkiya. 1989. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. Proc. Natl. Acad. Sci. USA. 86:2766-2770.
15. Williams, A.F., J.L. Strominger, J. Bell, T.W. Mak, J. Kappler, P. Marrack, B. Arden, M.P. Lefranc, L. Hood, S. Tonegawa, and M. Davis. 1995. Nomenclature for T-cell receptor (TCR) gene segments of the immune system. Immunogenetics. 42:451-453.
16. Arden, B., S.P. Clark, D. Kabelitz, and T.W. Mak. 1995. Human T-cell receptor variable gene segment families. Immunogenetics. 42:455-500.
17. Moss, P.A.H., and J.I. Bell. 1995. Sequence analysis of the human alpha/ beta T-cell receptor CDR3 region. Immunogenetics. 42:10-18.
18. Toyonaga, B., Y. Yoshikai, V. Vadasz, B. Chin, and T.W. Mak. 1985. Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain. Proc. Natl. Acad. Sci. USA 82:8624-8628.
19. Browning, M.J., P. Krausa, A. Rowan, D.C. Bicknell, J.G. Bodmer, and W.F. Bodmer. 1993. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc. Natl. Acad. Sci. USA. 90:2842-2845.
20. Anichini, A., A. Mazzocchi, G. Fossati, and G. Parmiani. 1989. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J. Immunol. 142:3692-3701.
21. Parham, P., C.J. Barnstable, and W.F. Bodmer. 1979. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J. Immunol. 123:342-349.
22. Russo, C., A.K. Ng, M.A. Pellegrino, and S. Ferrone. 1983. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics. 18:23-35.
23. Jorgensen, J.L., U. Esser, B. Fazekas de St. Groth, P.A. Reay, and M.M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. Nature (Lond.). 355:224-230.
24. Holmes, N., P. Ennis, A.M. Wan, D.W. Denney, and P. Parham. 1987. Multiple genetic mechanisms have contributed to the generation of the HLA-A2/A28 family of class I MHC molecules. J. Immunol. 139:936-941.
25. Romero, P., C. Pannetier, J. Herman, C.V. Jongeneel, J.C. Cerottini, and P.G. Coulie. 1995. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. Exp. Med. 182:1019-1028.
26. Farina, C., P. Van der Bruggen, P. Boël, G. Parmiani, and M.L. Sensi. 1996. Conserved TCR usage by HLA-Cw*1601-restricted T cell clones recognizing melanoma antigens. Int. Immunol. 8:1463-1466.
27. Sato, T., H.C. Maguire, Jr., M.J. Mastrangelo, and D. Berd. 1995. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin. Immunol. Immunopathol. 74:35-43.
28. Martin, S., and H.U. Weltzien. 1994. T cell recognition of haptens, a molecular view. Int. Arch. Allergy Immunol. 104:10-16.
29. Lattime, E.C., M.J. Mastrangelo, O. Bagasra, W. Li, and D. Berd. 1995. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother. 41:151-156.
30. Becker, J.C., C. Czerny, and E.B. Brocker. 1994. Maintenance of clonal anergy by endogenously produced IL-10. Int. Immunol. 6:1605-1612.
31. Groux, H., M. Bigler, J.E. De Vries, and M.G. Roncarolo. 1996. Interleukin-10 induces a long term antigen-specific anergic state in human CD4+ T-cells. J. Exp. Med. 184:19-31.
32. Mackensen, A., G. Carcelain, S. Viel, M.-C. Raynal, H. Michalaki, F. Triebel, J. Bosq, and T. Hercend. 1994. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93:1397-1402.
33. thor Straten, P., J.C. Becker, T. Seremet, E.B. Brocker, and J. Zeuthen. 1996. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J. Clin. Invest. 98:279-284.
34. Sensi, M., S. Salvi, C. Castelli, C. Maccalli, A. Mazzocchi, R. Mortarini, G. Nicolini, M. Herlyn, G. Parmiani, and A. Anichini. 1993. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: Tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J. Exp. Med. 178:1231-1246.
35. Mazzocchi, A., F. Belli, L. Mascheroni, C. Vegetti, G. Parmiani, and A. Anichini. 1994. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer. 58:330-339.
36. Anichini, A., R. Mortarini, C. Maccalli, P. Squarcina, K. Fleischhauer, L. Mascheroni, and G. Parmiani. 1996. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156:208-217.
37. Sensi, M., C. Traversari, M. Radrizzani, S. Salvi, C. Maccalli, R. Mortarini, L. Rivoltini, C. Farina, G. Nicolini, T. Wölfel, et al. 1995. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. Natl. Acad. Sci. USA. 92:5674-5678.